1313026-26-4

Basic information

• Product Name: rac-4-(1-hydroxybut-3-yn-1-yl)-2-nitrophenol
• Synonyms: rac-4-(1-hydroxybut-3-yn-1-yl)-2-nitrophenol
• CAS NO: 1313026-26-4
• Molecular Weight: 207.186
• Mol File: 1313026-26-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: rac-4-(1-hydroxybut-3-yn-1-yl)-2-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: rac-4-(1-hydroxybut-3-yn-1-yl)-2-nitrophenol(1313026-26-4)
• EPA Substance Registry System: rac-4-(1-hydroxybut-3-yn-1-yl)-2-nitrophenol(1313026-26-4)

Safety Data

• Hazardous Substances Data: 1313026-26-4(Hazardous Substances Data)

Upstream product

• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 106-96-7 propargyl bromide 

Downstream Products

• 1352435-32-5 C₂₃H₂₅NO₁₃ 
• 1352435-33-6 C₂₉H₃₉NO₁₃Si 
• 1374694-30-0 C₅₉H₆₀N₂O₂₈ 
• 1352435-38-1 C₃₈H₃₆N₂O₂₀ 
• 1352435-37-0 C₃₁H₃₃NO₁₆ 
• 1352435-36-9 C₃₇H₄₇NO₁₆Si 
• 1352435-35-8 C₂₅H₃₅NO₁₀Si 
• 1352435-34-7 C₂₃H₃₃NO₁₀Si 

Relevant articles and documents

The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy

Massive attack: Galactoside prodrugs have been designed that can be selectively activated by lysosomal β-galactosidase located inside cancer cells expressing a specific tumor-associated receptor. This efficient enzymatic process triggers a potent cytotoxic effect, releasing the potent antimitotic agent MMAE and allowing the destruction of both receptor-positive and surrounding receptor-negative tumor cells. Copyright

CONJUGATES AND PRODRUGS FOR TREATING OF CANCER AND INFLAMMATORY DISEASES

The present invention relates to the field of cancer and inflammatory diseases. More particularly, it aims to provide, for these purposes, novel conjugated forms of active ingredients belonging to the dolastatin family and having the formula as follows: It is also directed towards prodrug forms of these conjugates.